Our data suggest that BET inhibition in vivo may have significant metabolic consequences via effects on AKT-FOXO signalling, as well as suggesting that AKT may be a key pharmacological target of BET inhibition in anti-tumour therapy. The gene discussed is AKT1; the disease is neoplasm.